Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure (OPRA-HF)
2020-005176-35Phase 2Active
- Sponsor
- Sahlgrenska University Hospital
- Start
- Nov 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) comparing SZC (Lokelma) + MRA with Placebo + MRA (2 arms). Started Nov 2020; status: active.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2020-005176-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005176-35.